Association between tumor markers (CA125, CA15-3) and homozygous sickle cell anemia

Basit Öğe Kaydı
dc.contributor.authorKavvasoglu, Gamze Hande
dc.contributor.authorKavvasoglu, Baris
dc.contributor.authorKaya, Hasan
dc.date.accessioned2024-09-18T20:57:00Z
dc.date.available2024-09-18T20:57:00Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim: Sickle Cell Anemia (SCA) is a systemic and chronic inflammatory disease and is one of the most common hemoglobinopathies in the world and in our country. Cancer antigen 15-3 (CA15-3) and cancer antigen (CA125) have an important place in cancer screening, treatment follow-up and disease follow-up today. However, it has been shown that it may be high in some diseases other than these purposes. In this study, we also planned to determine the relationship between tumor markers and patients with SCA, which is a chronic inflammatory and ischemic disease. Material and Methods: Patients over the age of 18 who were diagnosed with homozygous SCA and followed up in the Department of Internal Diseases of Hatay Mustafa Kemal University Health Practice and Research Hospital and applied to the outpatient clinic were included in the study. Height, weight, body mass index (BMI) and waist circumference of all patients were measured. Echocardiographic examination was performed. Blood samples were collected from the patients to study CA125 and CA15-3 on appropriate days and conditions. Results: A total of 34 patients, 19 female and 15 male, and 35 healthy volunteers, 16 female and 19 male, were included in the study. In the echocardiographic examinations, the ejection fraction was normal in the control and SCA groups, and no signs of pericardial effusion were found. The mean CA15-3 of the patients with SCA was 56.42 +/- 23.73 U/ml, the mean of CA15-3 of the control group was 9.99 +/- 4.62 U/ml, and there was a statistically significant difference (p=0,001). The median CA125 value of patients with SCA was calculated as 5.95 U/ml, while the highest was 99 U/ml and the lowest was 1.8 U/ml. While the median CA125 value of the control group was calculated as 6 U/ml, the highest measurement was 17.8 U/ml and the lowest measurement was 0.7 U/ml. There was no any statistically significant difference between the groups. Discussion: Although the CA15-3 level was high in patients with SCA, the CA125 level was normal. We think that CA15-3 level is important in understanding the pathophysiology and mechanism of SCA and in terms of follow-up. Our study should be supported by studies with large patient participation.en_US
dc.identifier.doi10.4328/ACAM.21303
dc.identifier.endpage1313en_US
dc.identifier.issn2667-663X
dc.identifier.issue12en_US
dc.identifier.startpage1309en_US
dc.identifier.urihttps://doi.org/10.4328/ACAM.21303
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12230
dc.identifier.volume13en_US
dc.identifier.wosWOS:000895809100004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherBayrakol Medical Publisheren_US
dc.relation.ispartofAnnals of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSickle Cell Anemiaen_US
dc.subjectCA125en_US
dc.subjectCA15-3en_US
dc.titleAssociation between tumor markers (CA125, CA15-3) and homozygous sickle cell anemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu